AU615524B2 - The use of psg5 as a temperature-sensitive plasmid - Google Patents

The use of psg5 as a temperature-sensitive plasmid Download PDF

Info

Publication number
AU615524B2
AU615524B2 AU31582/89A AU3158289A AU615524B2 AU 615524 B2 AU615524 B2 AU 615524B2 AU 31582/89 A AU31582/89 A AU 31582/89A AU 3158289 A AU3158289 A AU 3158289A AU 615524 B2 AU615524 B2 AU 615524B2
Authority
AU
Australia
Prior art keywords
temperature
plasmid
marker
dna
psg5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU31582/89A
Other versions
AU3158289A (en
Inventor
Gunter Muth
Bernhard Nussbaumer
Alfred Puhler
Wolfgang Wohlleben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of AU3158289A publication Critical patent/AU3158289A/en
Application granted granted Critical
Publication of AU615524B2 publication Critical patent/AU615524B2/en
Assigned to AVENTIS PHARMA DEUTSCHLAND GMBH reassignment AVENTIS PHARMA DEUTSCHLAND GMBH Alteration of Name(s) in Register under S187 Assignors: HOECHST AKTIENGESELLSCHAFT
Assigned to SANOFI-AVENTIS DEUTSCHLAND GMBH reassignment SANOFI-AVENTIS DEUTSCHLAND GMBH Request to Amend Deed and Register Assignors: AVENTIS PHARMA DEUTSCHLAND GMBH
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/76Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Actinomyces; for Streptomyces

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The streptomycetes plasmid pSG5 is temperature-sensitive. It is thus possible with the aid of the pSG5 replicon to prepare temperature-sensitive hybrid plasmids. The latter are suitable for screening for DNA segments which are homologous with DNA segments of the hybrid plasmid.

Description

Its OIfficrs as prsucribed Oy lyl o o -;?'MW9T 22 03/a,-- Reg istered Palent Atto Registered Patent Atto rney TimE COMMISSIONr-R OF PATENTS.
Edwd. WAters Son', Mheioul no.
I -ur 61552 4,, COMMONWEALTH OF AUSTRALIA PATENTS ACT 1952-69 COMPLE TE SPECIFICATION
(ORIGINAL)
Class Int. Class Application Number: Lodged: Complete Specification Lodged: a Complete Specification Lodged: Accepted: Published: Priority
I
Related Art:
I-
Name of Applicant: Address of Applicant: p Actual Inventor: Address for Service: HOECHST AKTIENGESELLSCHAFT 50 Bruningstrasse, D-6230 Frankfurt/Main Federal Republic of Germany WOLFGANG WOHLLEBEN, GUNTER MUTH, ALFRED PUHLER and BERNHARD NUSSBAUMER EDWD. WATERS SONS, QUEEN STREET, MELBOURNE, AUSTRALIA, 3000.
Complete Specification for the invention entitled: THE USE OF pSG5 AS A TEMPERATURE-SENSITIVE
PLASMID
The following statement is a full description of this invention, including the best method of performing it known to us
I.
PAT 510 Prokurist Authorized SignatOry ppa. Tergau i.V. Lapice S-la- HOECHST AKTIENGESELLSCHAFT HOE 88/F 069 Dr.KL/rh Description The use of pSG5 as a temperature-sensitive plasmid European Patent (EP-B) No. 0,158,872 discloses the Streptomycetes plasmid pSG5 which can be isolated from a culture of Streptomyces ghanaensis DSM 2932. This plasmid is suitable for the preparation of hybrid vectors, for example for what are called shuttle vectors, which can, because of an incorporated E. coli replicon, be multiplied in E. coli strains. Vectors of this type are disclosed, for example, in the European Patent Applicaa. tion with the publication No. (EP-A) 158,201.
It has now been found that pSG5 is temperature-sensitive.
The property of temperature-sensitivity for pSG5 is 15 surprising because as yet no natural Streptomycetes plasmids having this property have been disclosed. Since pSG5 and the hybrid plasmids prepared with its replicon exhibit a wide host range, the new use of this plasmid according to the invention provides those skilled in the 0 art with a large number of possibilities: When a plasmid which has the replicon of pSG5, containing a marker, is constructed and used to transform a compatible host strain, and then the temperature is raised above the threshold, the only transformants obtained after selection for the marker are those which have the plasmid integrated, in whole or in part, into the genome.
Since such integrations essentially take place only in homologous regions of the genome, this method is suitable for finding such homologous regions in the genome of the host strain.
EP-A 0,243,856 discloses a method for the preparation of mutants, which comprises isolating from the starting
I
-2strain the complete DNA, converting it into short fragments, integrating these into a plasmid which contains a marker, is temperature-sensitive and replicates in the starting strain, and transforming the resulting hybrid population into the starting strain, selecting the transformants by selection for the marker, eliminating the hybrid plasmids by increasing the temperature above the threshold of the temperature-sensitive plasmid, and selecting the mutants by renewed selection for the marker.
The term "short" fragments denotes DNA sections which are obtained with restriction enzymes which cut many times, 9 such as Sau3A or TaqI, but also with mechanical methods (ultrasound, shearing) and which contain neither the promoter region nor the translation stop signals.
Because the only cells surviving after elimination of the I plasmids in a selection for the marker are those which have taken up the plasmid DNA into their chromosome H (which preferably takes place via the homologous DNA 20 integrated in the plasmid), the mutants are obtained directly.
The plasmid pSG5 is mentioned in EP-A 0,243,856 as a suitable starting plasmid. However, it is now possible according to the invention to dispense with mutation to give temperature-sensitive replication mutants when this plasmid is used. This means that not only are the mutation and the particularly elaborate selection dispensed with, but also the risk of generating undesired multiple mutations is avoided. The plasmid pSG5 is thus particularly well suited for this method.
The temperature-sensitivity of pSG5 is manifested in such a way that this plasmid becomes unstable and is no longer replicated at temperatures at or above 36°C. The upper limit of the utilizable temperature range depends on the host cell: it is, for example, 38 0 C in S. venezuelae, 39 0
C
r 3 in S. lividans and 45 0 C with S. ghanaensis. When cultures which contain pSG5 or a derivative of this plasmid are incubated at a temperature of 36 0 C or above, the "plasmid becomes diluted out" and is no longer detectable after a few generations.
:0
IS
S 0 0.
S
0 S. OS @5 0 0 The use, according to the invention, of the pSG5 replicon can thus be utilized to find genes which are homologous to an existent gene. Thus a utilizable alternative to setting up a gene bank and screening with labeled DNA probes is available. This alternative is especially valuable when the result obtained from hybridization has not been conclusive. Another advantage of this method is that it is possible to avoid working with radioactive substances.
It is also possible correspondingly to find insertion elements (IS elements) and transposons which have been taken up into the genome of the host strain investigated: If, specifically, the plasmid which has been provided only with the marker and contains no other inserted DNA is used, then homologous regions are available only if an IS element or transposon has been transferred from the chromosome to the plasmid before raising the temperature.
Hence selection for the marker makes it possible to find such DNA elements.
5* a
O
00 *5 00
S.
The said investigations can be carried out in accordance with the method for isolating mutants described in EP-A 0,243,856.
Thus the invention is associated with a number of advantages: 1. There already exists a family of vectors which is based on the pSG5 plasmid and, because of the wide host range, has a large variety of possible uses and which has various selection markers such as resistance to neomycin, thiostrepton, kanamycin (EP-A 0,158,201) and gentamicin (EP-A 0,248,207) as well as color markers such as melanin ll. li_- L311~ and other coloring substances or pigments (EP-A 0,257,416 I and 0,257,417).
2. It is possible, by use of a plasmid which belongs to the said family of vectors and contains a marker which can be selected in E. coli, to extend the method disclosed in EP-A 0,243,856 to the use of cosmid banks and thus to the isolation of large DNA sections of about kb: if the marker which can be selected in E. coli is integrated into the host chromosome, the genome of the mutants produced in this way can be transferred into a cosmid gene bank. Selection for the marker (expediently at the same time as the marker intrinsic to the cosmid) then immediately leads to the cosmid clone of interest.
In this way the extremely elaborate screening by hybridization which was hitherto necessary is dispensed with. In 0: 0 0 contrast to the method disclosed in EP-A 0,243,856, it is thus possible to detect in one step large gene regions in the neighborhood of the mutated gene. Gene clusters can be isolated in this way, that is to say, for example, the genes for an entire biosynthetic pathway. Nor is there any longer a need for cleavage sites suitable for restriction enzymes to be present in the vicinity of the mutated gene.
The invention is explained in detail in the examples 00 which follow. Unless indicated otherwise, percentage data O herein relate to weight.
Example 1: Complete DNA isolation 0.1 g of mycelium from a 3-day old homogenized Streptomycetes culture of the strain S. ghanaensis (ATCC 14672; US Patent 3,674,866), which produces no melanin (mel-), is pelleted in a 1.5 ml Eppendorf reaction tube in an Eppendorf centrifuge for 1 min and then washed once with ml of TE (10 mM tris-HCl, 1 mM EDTA (pH 8) containing sucrose). The pellet is then resuspended in 0.5 ml of lysozyme solution (0.3 M sucrose, 25 mM tris-HCl (pH 8), mM EDTA, 10 mg/ml lysozyme) and incubated at 370C for min. 0.2 ml of 5% strength SDS solution is added and then the solution is thoroughly mixed and incubated at 0 C for 10 min and subsequently cooled again to room temperature. Then 100 pl of phenol/chloroform (5 g of phenol, 5 ml of chloroform, 5 mg of 8-hydroxyquinoline, 1 ml of 0.1 M tris (pH are added, and the suspension is mixed cautiously on a shaker (R"Vortex) until it is homogeneous. The mixture is then centrifuged in an Eppendorf centrifuge for 5 min, and the upper aqueous phase is transferred into a new reaction tube. 70 l of 3 A unbuffered sodium acetate and 700 pl of isopropanol "are added to the DNA-containing solution. After mixing and incubation at room temperature for 15 minutes, the DNA is pelleted by centrifugation (5 min in an Eppendorf centrifuge), and the supernatant is removed quantitatively. The DNA is resuspended in 300 pl of TE and then I incubated with 10 pl of RNase solution (50 ug of RNase/ml of H 2 0) at 37 0 C for 45 min. The RNase is inactivated by I 100 pl of phenol/chloroform, and the denatured proteins are pelleted (5 min in an Eppendorf centrifuge). The DNA- 0.
containing solution is again treated with isopropanol (addition of 30 l of 3 M sodium acetate and 400 pl of isopropanol, incubation at room temperature for 15 min).
The DNA pellet obtained after centrifugation is washed twice with 70% strength ethanol and again pelleted. After the DNA has been dried it is taken up in 300 pl of TE and used for the further steps.
SI Example 2: Cleavage of the complete DNA with Sau3A 1 pg of DNA is incubated in cleavage buffer (50 mM tris- HC1 (pH 10 mM MgCl 2 50 mM NaC1) in the presence of 1 unit of Sau3A (manufactured by BRL-Gibco, Karlsruhe) at 37°C for 1 h. The reaction is stopped by phenol treatment, and the DNA is purified by ethanol precipitation.
6 Example 3: Cloning of fragments of complete DNA into the plasmid pGM4 pGM4 (EP-A 0,257,416 and 0,257,417) is completely linearized with BamHI in analogy to Example 2. The two DNA samples are mixed in cleavage buffer, heated to 70oC and adjusted to the ligase reaction conditions by addition of mercaptoethanol (final conc. 10 mM) and ATP (0.1 mM). The mixture is incubated in the presence of 1 unit of T4 DNA ligase (Boehringer Mannheim) at 14 0 C for 12 h. The mixture S, is then transformed into protoplasts of the starting strain and plated out on regeneration plates. After about 20 h, a top layer of soft agar which contains sufficient thiostrepton for the final concentration in the plate to be 50 pg/ml is placed on the latter.
a Example 4: Generation and selection of mutants The transformants are incubated in S medium (Hopwood et al., "Genetic Manipulation of Streptomyces, a Laboratory i Manual", The John Innes Foundation, Norwich 1985) in a shake culture at 28 0 C for about 36 h. The temperature is then raised to 39 0 C and incubation is continued at this temperature for about 36 h. The culture is harvested S sterile, washed in TE 10% sucrose and incubated in complete medium containing thiostrepton (20 mg/l) at 39 0
C
for a further 48 h. The mutants generated in this way are then plated out and characterized (incubation always at 39 0
C).
Example 5: Isolation of the mutated DNA The DNA is isolated as in Example 1 from the mutants, is cut with a restriction enzyme which has no cleavage sites in the integrated plasmid, and is religated with T4 DNA ligase. This results in the integrated plasmid, which now contains the mutated gene, being formed as the only cyclic DNA capable of replication. Retransformation into a suitable strain such as S. lividans is followed by 2 *7 selection for thiostrepton resistance and isolation of the plasmid which harbors the mutated gene from the transformants.
The following published Australian patent applications, which are hereby incorporated by reference, correspond to the above-mentioned European specifications: EP-B 0,158,872 AU-A 40,599/85 EP-A 0,158,201 AU-A 40,600/85 o EP-A 0,257,416 AU-A 76,803/87 SEP-A 0,257,417 AU-A 76,802/87 I a I a' ft q

Claims (7)

1. A process for making a plasmid, which is capable of replicating in Streptomycetes and is temperature-sensitive, which comprising ligating DNA containing the replicon of as herein before defined which has not been treated to confer temperature-sensitivity with foreign DNA said foreign DNA not providing the property of temperature-sensitivity.
2. The process as claimed in claim 1, wherein the foreign DNA contains a marker. 0.
3. A method for finding insertion elements and S transposons, which comprises providing the plasmid pSG5 as 0 I ,herein before defined which has not been treated to confer temperature-sensitivity with a marker, transforming a Streptomycetes strain with the hybrid plasmid obtained in this way, incubating the transformants at a temperature above 36 0 C, selecting transformants expressing the marker, and analyzing the DNA region where recombination has taken place in said transformants. SS
4. A method for the preparation of Streptomycetes mutants, for the isolation of the mutated genes and for the isolation of the corresponding wild-type gene, which comprises isolating from the starting Streptomycetes strain the complete DNA, converting it into short fragments, Iintegrating these into a hybrid plasmid which has the replicon, containing a marker, and transforming the resulting hybrid plasmid population into the starting strain, selecting the transformants by selection for the marker, eliminating the hybrid plasmids by increasing the temperature above the threshold, and selecting the mutants by renewed selection for the marker wherein said i i 8a portion of the hybrid plasmid has not been treated to confer temperature-sensitivity.
The method as claimed in claim 4 wherein the mutated genes are isolated from the selected mutants.
6. The method as claimed in claim 5, wherein the corresponding wild-type genes are isolated using the mutated genes.
7. The method as claimed in claim 5, wherein the hybrid plasmid having the pSG5 replicon contains arker which can be selected in E. coli, and wherein a cosmid bank S is used in the isolation of the mutated genes. o* DATED this 23rd day of May 1991. HOECHST AKTIENGESELLSCHAFT WATERMARK PATENT TRADEMARK ATTORNEYS THE ATRIUM 290 BURWOOD ROAD HAWTHORN, VICTORIA 3122 AUSTRALIA DBM/JMW/CH (3:21)
AU31582/89A 1988-03-23 1989-03-22 The use of psg5 as a temperature-sensitive plasmid Expired AU615524B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3809692 1988-03-23
DE3809692A DE3809692A1 (en) 1988-03-23 1988-03-23 USE OF PSG5 AS A TEMPERATURE-SENSITIVE PLASMIDE

Publications (2)

Publication Number Publication Date
AU3158289A AU3158289A (en) 1989-09-28
AU615524B2 true AU615524B2 (en) 1991-10-03

Family

ID=6350421

Family Applications (1)

Application Number Title Priority Date Filing Date
AU31582/89A Expired AU615524B2 (en) 1988-03-23 1989-03-22 The use of psg5 as a temperature-sensitive plasmid

Country Status (16)

Country Link
EP (1) EP0334282B1 (en)
JP (1) JP2770975B2 (en)
KR (1) KR970003961B1 (en)
AT (1) ATE108485T1 (en)
AU (1) AU615524B2 (en)
CA (1) CA1335964C (en)
DE (2) DE3809692A1 (en)
DK (1) DK175475B1 (en)
ES (1) ES2056987T3 (en)
FI (1) FI95394C (en)
HU (1) HU213350B (en)
IE (1) IE63496B1 (en)
IL (1) IL89686A (en)
NO (1) NO178157C (en)
PT (1) PT90090B (en)
ZA (1) ZA892123B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3809691A1 (en) * 1988-03-23 1989-10-12 Hoechst Ag METHOD FOR SELECTION OF LARGE DNA SECTIONS
DE4011863A1 (en) * 1990-04-12 1991-10-17 Hoechst Ag REGULATED GENE EXPRESSION IN STREPTOMYCETES
FR2688515B1 (en) * 1992-03-13 1995-03-31 Institut Rech Agronomique THERMOSENSITIVE PLASMID.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0158872A1 (en) * 1984-03-31 1985-10-23 Hoechst Aktiengesellschaft Streptomycetes plasmid pSG5, process for its preparation and its use
EP0243856A2 (en) * 1986-04-28 1987-11-04 Hoechst Aktiengesellschaft Process for the isolation of mutants, mutant genes and corresponding wild-type genes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3412093A1 (en) * 1984-03-31 1985-10-10 Hoechst Ag, 6230 Frankfurt HYBRID PLASMIDE WITH A STREPTOMYCETE AND ESCHERICHIA COLI REPLICON
DE3627392A1 (en) * 1986-08-13 1988-04-28 Hoechst Ag COLOR MARKER FOR CLONING IN STREPTOMYCES LIVIDANS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0158872A1 (en) * 1984-03-31 1985-10-23 Hoechst Aktiengesellschaft Streptomycetes plasmid pSG5, process for its preparation and its use
EP0243856A2 (en) * 1986-04-28 1987-11-04 Hoechst Aktiengesellschaft Process for the isolation of mutants, mutant genes and corresponding wild-type genes

Also Published As

Publication number Publication date
DE58908022D1 (en) 1994-08-18
DE3809692A1 (en) 1989-10-12
IE63496B1 (en) 1995-05-03
NO891267D0 (en) 1989-03-22
KR970003961B1 (en) 1997-03-24
IL89686A0 (en) 1989-09-28
CA1335964C (en) 1995-06-20
NO178157B (en) 1995-10-23
PT90090A (en) 1989-11-10
FI95394C (en) 1996-01-25
ATE108485T1 (en) 1994-07-15
NO891267L (en) 1989-09-25
FI95394B (en) 1995-10-13
KR890014741A (en) 1989-10-25
ZA892123B (en) 1989-11-29
HU213350B (en) 1997-05-28
NO178157C (en) 1996-01-31
AU3158289A (en) 1989-09-28
JP2770975B2 (en) 1998-07-02
DK146089A (en) 1989-09-24
JPH029376A (en) 1990-01-12
EP0334282A2 (en) 1989-09-27
PT90090B (en) 1994-06-30
DK146089D0 (en) 1989-03-22
FI891335A0 (en) 1989-03-21
HUT50511A (en) 1990-02-28
FI891335A (en) 1989-09-24
DK175475B1 (en) 2004-11-08
EP0334282B1 (en) 1994-07-13
EP0334282A3 (en) 1989-11-29
ES2056987T3 (en) 1994-10-16
IL89686A (en) 1994-12-29
IE890898L (en) 1989-09-23

Similar Documents

Publication Publication Date Title
Kuspa et al. Tagging developmental genes in Dictyostelium by restriction enzyme-mediated integration of plasmid DNA.
US4732856A (en) Transposable elements and process for using same
JPH0239889A (en) Macloride biosynthetic gene for use in streptomyces and other organisms
JP2540143B2 (en) Recombinant DNAs and uses thereof
Chung Tn4556, a 6.8-kilobase-pair transposable element of Streptomyces fradiae
Flett et al. DNA deletions in spontaneous chloramphenicol-sensitive mutants of Streptomyces coelicolor A3 (2) and Streptomyces lividans 66
AU615524B2 (en) The use of psg5 as a temperature-sensitive plasmid
DE68918532T2 (en) Recombinant DNA encoding a 4 '' - 0-isovalerylacylase.
EP0213898B1 (en) A host-vector system
US4992371A (en) Hybrid plasmids having a streptomycetes replicon and an escherichia coli replicon
JPS62259592A (en) Isolation of mutation gene and corresponding wile type gene of mutant
US4880746A (en) Streptomycetes plasmid PSG5, a process for obtaining it, and its use
US5665564A (en) Isolation and characterisation of genes resistant to anthracycline antibiotics
NZ228441A (en) Psg5 plasmid used in isolating is elements, transposons and mutated genes
Manis et al. Partial characterization of a small, multi-copy plasmid from Streptomyces espinosus and the derivation of a high copy-number deletion mutant
US5776735A (en) Process for dienone macrolides
EP0620280A1 (en) Cosmid vectors for streptomycetes genomic DNA cloning
AU610411B2 (en) Isolation and characterisation of genes resistant to anthracycline antibiotics
IE913588A1 (en) Transformant selection marker system
GB2153363A (en) Method of preparation of cloning vector
EP0618297A1 (en) Novel bacterial plasmid shuttle vectors for streptomycetes and escherichia coli
JPS585187A (en) Novel plasmid
WO1999006570A2 (en) Plasmids

Legal Events

Date Code Title Description
PC Assignment registered

Owner name: AVENTIS PHARMA DEUTSCHLAND GMBH

Free format text: FORMER OWNER WAS: HOECHST AKTIENGESELLSCHAFT